Sepsis News
-
Staphylococcus aureus and Mitigating Exposure Risks in Occupational, Healthcare and Community Settings
Frequently referred to as staph, Staphylococcus aureus is a type of bacteria that is commonly found on the skin and hair, as well as in the nose and throat of people and animals. In fact, the Centers for Disease Control and Prevention (CDC) reports that about 30% of people carry Staphylococcus aureus in their nose. While most of the time staph does not cause harm to healthy individuals, it has ...
-
Protecting Patients, Workers and Building Occupants from Staphylococcus aureus and Other Pathogens in Puerto Rico
Staphylococcus aureus is a type of bacteria that has long been recognized as a cause of disease. Frequently referred to as staph, it is commonly found on the skin and hair, as well as in the nose and throat of people and animals. The Centers for Disease Control and Prevention (CDC) even reports that about 30% of people carry Staphylococcus aureus in their nose. Most of the time, staph does not ...
-
New partnership to advance glycoproteomics and biotherapeutics tools and research
Protein Metrics Inc., a leading provider of biopharmaceutical and proteomics analysis software, announced today a new partnership to advance glycoproteomics and biotherapeutics tools and research Macquarie University’s Analytical Glycoimmunology Group and Protein Metrics Inc. today have launched a strategic partnership scheme to further advance glycoproteomics and biotherapeutics ...
-
Is data drift an issue for medical AI models - and what can we do about it?
While medical AI has many potential benefits, there are challenges that have not been tackled yet. One of the major challenges is the limited generalizability of many AI algorithms. Applying a medical AI algorithm that is trained in hospital A may give unexpected results when applied in hospital B. Why does this happen? Certain parameters are different between hospitals. If hospital A has Siemens ...
By Segmed, Inc.
-
World Sepsis Day – Raising awareness about one of the most prevalent and deadly, yet misdiagnosed, medical conditions.
Sepsis is the body’s over active and toxic response to an infection that causes hospitalization of more than 18 million people around the world every year, including 30,000 Canadians Declared a Global Health Priority by the World Health Organization in 2017 80% of sepsis deaths in hospitals could be prevented with rapid diagnosis and treatment Vancouver, Canada: Noting World Sepsis ...
-
CDRD Launches New Company Developing Life-Saving Sepsis Diagnostic
Marking “World Sepsis Day”, The Centre for Drug Research and Development (CDRD) announces the spin-off of a new company, Sepset Biosciences Inc. The company is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis – a global healthcare problem that is more common than heart attack and claims ...
-
Positive Clinical Results for Bluejay’s Symphony IL-6 Test Presented at AACC 2022
Demonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, ...
-
Accelerate Diagnostics Announces Launch Of Accelerate Arc Module and BC Kit
The Accelerate Arc System cuts hours of wait time and numerous manual steps to deliver Identification (ID) results Unlocks rapid microbial ID from positive blood cultures for the large installed base of MALDI system users Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, ...
-
WHO calls for new innovations to tackle antimicrobial resistance crisis
Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi Ondine’s nonantibiotic photodisinfection technology has been proven in Canadian hospitals to kill pathogens helping to generate 84% reduction of postoperative infection rates and significant cost savings. The World ...
-
Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced completion of its previously planned clinical studies for the Symphony IL-6 Test (the “Test”). Results of these studies will be ...
-
Creative Proteomics Cytokine Boosts Your Research and Discovery with Mouse Cytokine Assay
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently launched the Mouse Cytokine Assay with high sensitivity to support research in immune responses, inflammatory ...
-
Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test. In written feedback to the ...
-
Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that three Idylla™ study posters, of which two on the SeptiCyte® RAPID (developed in collaboration with Immunexpress) and one on the Idylla™ SARS-CoV-2 Test (CE-IVD) and Idylla™ SARS-CoV-2/Flu/RSV Panel (CE-IVD), ...
By Biocartis NV
-
Blood ties: The inspiration behind a potential sepsis breakthrough
Robert Hancock and Olga Peña—who lost her father to sepsis—may have found a way to diagnose the deadliest syndrome you’ve never heard of. The doctor suspected 70-year-old Augustin Peña had the flu, so he sent him home to rest and drink lots of fluids. But after three days of continuing to suffer, Peña entered the local hospital in Tolima, Colombia. His ...
-
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet; that no dividend is made; discharge from liability granted to Board members and the managing director, that the Board shall consist of ...
-
Creative Proteomics Cytokine Unveils Tumor Necrosis Factors (TNF) Detection Service
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently announced the launch of the high-sensitivity Tumor Necrosis Factors (TNF) Detection Service to help with your ...
-
Specific Diagnostics announces that Nathan Clark, former GenMark Sales Leader, joins Specific Diagnostics as Strategic Account Director, US East
Specific Diagnostics today announced the appointment of Nathan Clark as Strategic Account Director. Nathan was a key member of the GenMark sales leadership team, most recently as a sales manager for GenMark’s Northeast region, overseeing a team of 7 sales professionals and infectious disease specialists responsible for approximately $70M of revenue. Nathan was a critical part of the sales ...
-
SafeHeal Announces Successful Launch of IDE Study for Colovac Endoluminal Bypass Sheath
Paris, France, & Guilford, CT – April 1, 2022 – SafeHeal™, a leading innovator in the field of digestive surgery, recently announced the first patient enrollment in its pivotal study of Colovac™, a groundbreaking endoluminal bypass sheath. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal resection. Up to 20 U.S. ...
By SafeHeal
-
Infant Bacterial Therapeutics publishes Annual Report for 2021
Infant Bacterial Therapeutics AB (publ) publishes today the Annual Report for 2021. The report is available on IBT’s website ibtherapeutics.com under the section “Investors & Media – Financial Reports” and is available in printed form for those that have requested. A copy can be requested by contacting IBT’s office via info@ibtherapeutics.com. About Infant ...
-
Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin “Ed” E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you